Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies.
de Witte MA, Janssen A, Nijssen K, Karaiskaki F, Swanenberg L, van Rhenen A, Admiraal R, van der Wagen L, Minnema MC, Petersen E, Raymakers RAP, Westinga K, Straetemans T, Halkes CJM, Boelens JJ, Kuball J. de Witte MA, et al. Among authors: karaiskaki f. Blood Adv. 2021 Jan 12;5(1):240-249. doi: 10.1182/bloodadvances.2020002444. Blood Adv. 2021. PMID: 33570642 Free PMC article. Clinical Trial.
Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds.
van Diest E, Hernández López P, Meringa AD, Vyborova A, Karaiskaki F, Heijhuurs S, Gumathi Bormin J, van Dooremalen S, Nicolasen MJT, Gatti LCDE, Johanna I, Straetemans T, Sebestyén Z, Beringer DX, Kuball J. van Diest E, et al. Among authors: karaiskaki f. J Immunother Cancer. 2021 Nov;9(11):e003850. doi: 10.1136/jitc-2021-003850. J Immunother Cancer. 2021. PMID: 34815357 Free PMC article.
γ9δ2T cell diversity and the receptor interface with tumor cells.
Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, de Haas A, Sanders J, Janssen A, Straetemans T, Olive D, Leusen J, Boutin L, Nedellec S, Schwartz SL, Wester MJ, Lidke KA, Scotet E, Lidke DS, Heck AJ, Sebestyen Z, Kuball J. Vyborova A, et al. Among authors: karaiskaki f. J Clin Invest. 2020 Sep 1;130(9):4637-4651. doi: 10.1172/JCI132489. J Clin Invest. 2020. PMID: 32484803 Free PMC article.
Uncovering the mode of action of engineered T cells in patient cancer organoids.
Dekkers JF, Alieva M, Cleven A, Keramati F, Wezenaar AKL, van Vliet EJ, Puschhof J, Brazda P, Johanna I, Meringa AD, Rebel HG, Buchholz MB, Barrera Román M, Zeeman AL, de Blank S, Fasci D, Geurts MH, Cornel AM, Driehuis E, Millen R, Straetemans T, Nicolasen MJT, Aarts-Riemens T, Ariese HCR, Johnson HR, van Ineveld RL, Karaiskaki F, Kopper O, Bar-Ephraim YE, Kretzschmar K, Eggermont AMM, Nierkens S, Wehrens EJ, Stunnenberg HG, Clevers H, Kuball J, Sebestyen Z, Rios AC. Dekkers JF, et al. Among authors: karaiskaki f. Nat Biotechnol. 2023 Jan;41(1):60-69. doi: 10.1038/s41587-022-01397-w. Epub 2022 Jul 25. Nat Biotechnol. 2023. PMID: 35879361 Free PMC article.
Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells.
Hernández-López P, van Diest E, Brazda P, Heijhuurs S, Meringa A, Hoorens van Heyningen L, Riillo C, Schwenzel C, Zintchenko M, Johanna I, Nicolasen MJT, Cleven A, Kluiver TA, Millen R, Zheng J, Karaiskaki F, Straetemans T, Clevers H, de Bree R, Stunnenberg HG, Peng WC, Roodhart J, Minguet S, Sebestyén Z, Beringer DX, Kuball J. Hernández-López P, et al. Among authors: karaiskaki f. Nat Immunol. 2024 Jan;25(1):88-101. doi: 10.1038/s41590-023-01665-0. Epub 2023 Nov 27. Nat Immunol. 2024. PMID: 38012415